Insulet Launches Revolutionary iPhone App for Omnipod 5, Enhancing Type 1 Diabetes Management

      The FDA has recently cleared an innovative iPhone app developed by Insulet for its Omnipod 5 hybrid closed-loop system, specifically designed for people with type 1 diabetes. This development follows the app's earlier availability on Android devices. Insulet's announcement highlights a significant milestone: the Omnipod 5 now stands as the only tubeless automated insulin delivery (AID) system that can be fully controlled via a compatible smartphone.

      Initially, the iPhone app will be integrated with DexCom's G6 continuous glucose monitoring system, with which the Omnipod 5 exclusively operates. Anticipated for a full market release in 2024, this app represents a major step forward in the realm of diabetes management technology, offering enhanced convenience and control for users. Importantly, the app will be available at no additional cost to users of the Omnipod 5 System.

FDA Approves Zepbound for Weight Management in Adults with Obesity or Overweight Conditions

      The FDA has recently given the green light to Zepbound (tirzepatide) injection, a new medication for managing chronic weight in adults with obesity (BMI over 30 kg/m^2) or overweight (BMI over 27 kg/m^2) who also have weight-related health issues like high blood pressure, type 2 diabetes, or high cholesterol. This approval is for use in conjunction with a diet low in calories and increased physical activity.

      Zepbound works by activating specific hormone receptors in the intestines, namely glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This activation helps reduce appetite and food intake. The medication is administered through an under-the-skin injection once a week. Patients start with a lower dose, which is gradually increased over four to 20 weeks until the target doses of 5 mg, 10 mg, or 15 mg per week are reached, with 15 mg being the maximum weekly dosage.

      This approval by the FDA, granted to Eli Lilly and Co., marks a significant step forward in providing effective treatment options for individuals struggling with obesity or overweight, especially those also dealing with related health conditions.